Liver Diseases  >>  pidilizumab (CT-011)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pidilizumab (CT-011) / CureTech
NCT00966251: Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma

Terminated
1/2
2
RoW
CT-011
CureTech Ltd, Teva Branded Pharmaceutical Products R&D, Inc.
Primary Hepatocellular Carcinoma
06/11
06/11
NCT00962936: Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection

Terminated
1/2
13
RoW
CT-011
CureTech Ltd, Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Hepatitis C
10/11
01/13

Download Options